Abstract INTRODUCTION Validation of Alzheimer's disease blood‐based biomarkers (BBMs) has relied largely on amyloid beta (Aβ) and tau positron emission tomography (PET), with limited quantitative neuropathologic correlation studies. We examined associations between BBMs and quantitative postmortem neuropathology in 124...
Celia R. Bianco, Neus Rabaneda-Lombarte, Hadia A. Fatima et al.· Alzheimer's & Dementia· 0 citations
Higher plasma p-tau217 levels were consistently associated with increased risk of clinical progression and accelerated cognitive decline, and support the potential of p-tau217 for prognostic model development, with direct implications for future trial design.
R. Buckley, D. Townsend, C. Birkenbihl et al.· Journal of the American Medi...· 3 citations
It is reported that X-linked Dystonia-Parkinsonism (XDP), caused by a non-coding retrotransposon-associated repeat insertion in TAF1, involves a significant imbalance of tau isoforms and the accumulation of hyperphosphorylated, four-repeat tau in the brain.
C. J. Reyes, Aloysius Domingo, E. Penney et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.